<DOC>
	<DOCNO>NCT02392637</DOCNO>
	<brief_summary>The goal clinical research study learn add abraxane ( nab-paclitaxel ) gemcitabine cisplatin help control metastatic ( spread ) unresectable ( remove surgery ) biliary cancer . The safety drug combination also study .</brief_summary>
	<brief_title>Gemcitabine , Cisplatin , Abraxane Advanced Biliary Cancers</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , receive study drug 21-day study cycle . You receive 3 drug vein Days 1 8 cycle 2 hour total . You receive abraxane first , follow cisplatin , gemcitabine . Study Visits : On Days 1 8 cycle : - You physical exam . - Blood ( 2 tablespoon ) draw routine test . At end every 3rd cycle ( Cycles 3 , 6 , 9 , ) , MRI CT scan . If disease appear get good , another scan 3 cycle later . Length Study : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study last scan long-term follow-up . End-of-Treatment Visit : Within 10 day stop take study drug : - You physical exam . - Blood ( 2 tablespoon ) draw routine test . - If one last 4 week , MRI CT scan . Follow-Up : About 30 day last dose study drug , study staff ask symptom side effect may , either phone routine clinic visit . If call , last 15-30 minute . Long-Term Follow-Up : About every 12 week end-of-treatment visit , leave study reason disease get bad , MRI CT scan check status disease . If start receive anti-cancer treatment , stop scan . The study staff also review medical record and/or call check status disease every 3 month stop receive study drug . If call , take 5 minute . This investigational study . Abraxane FDA approve commercially available treatment melanoma , breast , pancreatic , lung cancer . The use abraxane patient biliary cancer consider investigational . Gemcitabine FDA approve commercially available treatment ovarian , biliary , pancreatic cancer . Cisplatin FDA approve commercially available treatment osteosarcoma , lung cancer , biliary cancer , malignant fibrous histiocytoma . Up 60 participant enrol multicenter study . Up 50 take part MD Anderson .</detailed_description>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Patient must histologically cytologically confirm intrahepatic cholangiocarcinoma , extrahepatic cholangiocarcinoma , gallbladder cancer may undergo repeat biopsy histologic confirmation preexist biopsy sufficient diagnosis . 2 . Metastatic unresectable disease document diagnostic imaging study . 3 . May receive prior chemotherapy . If patient receive prior adjuvant therapy , must &gt; 6 month treatment . 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . 5 . Adequate organ function include : ) Absolute neutrophil count ( ANC ) =/ &gt; 1,500 cells/mm^3 ; b ) Platelets =/ &gt; 100,000/ul ; c ) Hemoglobin &gt; 9.0 g/dL ; ) Total bilirubin =/ &lt; 1.5mg/dL ( In patient know Gilbert 's syndrome direct bilirubin =/ &lt; 1.5 x ULN use organ function criterion , instead total bilirubin ; e ) AST ALT =/ &lt; 5 x ULN ; f ) Creatinine =/ &lt; 1.5 gm/dL 6 . Negative serum urine pregnancy test woman childbearing potential ( WOCBP ) define postmenopausal 12 month previous surgical sterilization , within one week prior initiation treatment . WOCBP must use adequate method contraception avoid pregnancy throughout study 12 week last dose study drug minimize risk pregnancy . 7 . A male subject father potential must use adequate method contraception avoid conception throughout study 12 week last dose study drug minimize risk pregnancy . If partner pregnant breastfeeding , subject must use condom . 8 . Patients must sign Informed Consent Authorization indicate aware investigational nature study know risk involve . 9 . Patient =/ &gt; 18 year age day consent study . 1 . Peripheral neuropathy grade 2 great Common Terminology Criteria Adverse Events ( CTCAE ) 4.0 . In CTCAE version 4.0 grade 2 sensory neuropathy define `` moderate symptom ; limit instrumental activity daily live ( ADLs ) '' 2 . Concurrent severe and/or uncontrolled medical condition could compromise participation study unstable angina , myocardial infarction within 6 month , unstable symptomatic arrhythmia , uncontrolled diabetes , serious active uncontrolled infection . 3 . Pregnancy ( positive pregnancy test ) lactation . 4 . Known CNS disease , except treat brain metastasis . Treated brain metastasis define evidence progression hemorrhage treatment ongoing requirement dexamethasone , ascertain clinical examination brain imaging ( MRI CT ) screen period . Anticonvulsants ( stable dose ) allow . Treatment brain metastasis may include whole brain radiotherapy ( WBRT ) , radiosurgery ( RS ; Gamma Knife , LINAC , equivalent ) combination deem appropriate treating physician . Patients CNS metastasis treat neurosurgical resection brain biopsy perform within 3 month prior Day 1 exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Biliary Tract Cancer</keyword>
	<keyword>Intrahepatic cholangiocarcinoma</keyword>
	<keyword>Extrahepatic cholangiocarcinoma ,</keyword>
	<keyword>Gallbladder cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Unresectable</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Nab-Paclitaxel</keyword>
	<keyword>Paclitaxel ( Protein-Bound )</keyword>
	<keyword>ABI-007</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Platinol-AQ</keyword>
	<keyword>Platinol</keyword>
	<keyword>CDDP</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemcitabine Hydrochloride</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Phone call</keyword>
</DOC>